- Meeting abstract
Continuous infusion of propofol for sedation of pediatric patients following open-heart surgery
Critical Care volume 2, Article number: P056 (1998)
The aim of this study was to prospectively evaluate safety and efficacy of propofol infusion as an alternative sedative agent in children with open-heart surgery.
Twenty-nine pediatric patients with complex congenital lesions, aged between 4 and 48 months, who underwent open-heart surgery, received propofol infusion as sedation after midazolam infusion was ineffective. The effective sedative dose of propofol was between 1.5 and 7.0 mg/kg per h (median 3 mg/kg per h). Measurement of heart rate (HR) electrocardiogram (ECG), blood pressure (BP), arterial blood gas (ABG) including pH, bicarbonate (HCO3), partial carbon dioxide pressure (PCO2), and blood oxygen saturation (PO2); and blood chemistry including liver function tests (LFTs), triglycerides (TG), and total bilirubin (TB), were all done prior to and during propofol therapy.
After 10–288 h of propofol infusion (median 74 h), no statistically significant differences were found in the parameters measured except a decrease in median HR with attendant decrease in BP, and an increase in median TG.
Continuous sedation with propofol is a safe and effective, alternative agent for sedation of infants and children after surgical repair of compex congenital heart disease.
Rights and permissions
About this article
Cite this article
Darwish, A., Mousa, S., Afrane, B. et al. Continuous infusion of propofol for sedation of pediatric patients following open-heart surgery. Crit Care 2 (Suppl 1), P056 (1998). https://doi.org/10.1186/cc186
- Congenital Heart Disease
- Sedative Agent
- Blood Oxygen Saturation
- Continuous Sedation
- Partial Carbon Dioxide Pressure